118th Congress Health
S. 526: BENEFIT Act of 2023
Introduced
- Introduced (completed)
- Passed Senate (not reached)
- Passed House (not reached)
- To the President (not reached)
- Became law (not reached)
Summary
This bill requires the Food and Drug Administration (FDA) to consider relevant patient experience data in the risk-benefit assessment framework used in the process for approving new drugs.
After a new drug application has been approved, the FDA's public statement about how it used patient experience data shall include a description of how such data was considered in the risk-benefit assessment framework.
Written by the Congressional Research Service, Library of Congress.
Roll calls
No roll call votes have been held on this bill.
Amendments
No amendments were offered to this bill.
Cosponsors
- Amy Klobuchar D-MNOriginal
- Susan Collins R-ME
- Mike Braun R-IN
- Rick Scott R-FL
- Bill Hagerty R-TN
Who scored on this bill
- 1Roger Wicker SponsorDrew cross-party cosponsors, introduced2 events+6
See all scorers and every scoring event
Introductions and cosponsorships count toward weekly caps and show no points.
Other bills by Roger Wicker
- S. 3791: Regional Ocean Partnerships Reauthorization Act
- S. 3266: USMMA Athletics Act of 2026
- S. 4784: National Defense Authorization Act for Fiscal Year 2027
- S. 323: PLAN for Broadband Act
- S. 2126: Integrated Ocean Observation System Reauthorization Act of 2025
- S. 4164: To make technical corrections to the National Defense Authorization Act for Fiscal Year 2026
History
- Introduced in the Senate by Roger Wicker.
Show the full action history (2 actions)
- Introduced in Senate
- Read twice and referred to the Committee on Health, Education, Labor, and Pensions.